Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Susceptibility of Influenza A, B, C, and D Viruses to Baloxavir1.

Mishin VP, Patel MC, Chesnokov A, De La Cruz J, Nguyen HT, Lollis L, Hodges E, Jang Y, Barnes J, Uyeki T, Davis CT, Wentworth DE, Gubareva LV.

Emerg Infect Dis. 2019 Oct;25(10):1969-1972. doi: 10.3201/eid2510.190607. Epub 2019 Oct 17.

PMID:
31287050
2.

Detection of oseltamivir-resistant zoonotic and animal influenza A viruses using the rapid influenza antiviral resistance test.

Hodges EN, Mishin VP, De la Cruz J, Guo Z, Nguyen HT, Fallows E, Stevens J, Wentworth DE, Davis CT, Gubareva LV.

Influenza Other Respir Viruses. 2019 Jun 11. doi: 10.1111/irv.12661. [Epub ahead of print]

3.

Insights into the antigenic advancement of influenza A(H3N2) viruses, 2011-2018.

Jorquera PA, Mishin VP, Chesnokov A, Nguyen HT, Mann B, Garten R, Barnes J, Hodges E, De La Cruz J, Xu X, Katz J, Wentworth DE, Gubareva LV.

Sci Rep. 2019 Feb 25;9(1):2676. doi: 10.1038/s41598-019-39276-1.

4.

Assessing baloxavir susceptibility of influenza viruses circulating in the United States during the 2016/17 and 2017/18 seasons.

Gubareva LV, Mishin VP, Patel MC, Chesnokov A, Nguyen HT, De La Cruz J, Spencer S, Campbell AP, Sinner M, Reid H, Garten R, Katz JM, Fry AM, Barnes J, Wentworth DE.

Euro Surveill. 2019 Jan;24(3). doi: 10.2807/1560-7917.ES.2019.24.3.1800666.

5.

Monitoring influenza virus susceptibility to oseltamivir using a new rapid assay, iART.

Gubareva LV, Fallows E, Mishin VP, Hodges E, Brooks A, Barnes J, Fry AM, Kramp W, Shively R, Wentworth DE, Weidemaier K, Jacobson R.

Euro Surveill. 2017 May 4;22(18). pii: 30529. doi: 10.2807/1560-7917.ES.2017.22.18.30529.

6.

Antiviral Drug-Resistant Influenza B Viruses Carrying H134N Substitution in Neuraminidase, Laos, February 2016.

Baranovich T, Vongphrachanh P, Ketmayoon P, Sisouk T, Chomlasack K, Khanthamaly V, Nguyen HT, Mishin VP, Marjuki H, Barnes JR, Garten RJ, Stevens J, Wentworth DE, Gubareva LV.

Emerg Infect Dis. 2017 Apr;23(4):686-690. doi: 10.3201/eid2304.161876.

7.

A Pyrosequencing-Based Approach to High-Throughput Identification of Influenza A(H3N2) Virus Clades Harboring Antigenic Drift Variants.

Mishin VP, Baranovich T, Garten R, Chesnokov A, Abd Elal AI, Adamczyk M, LaPlante J, St George K, Fry AM, Barnes J, Chester SC, Xu X, Katz JM, Wentworth DE, Gubareva LV.

J Clin Microbiol. 2016 Dec 28;55(1):145-154. doi: 10.1128/JCM.01840-16. Print 2017 Jan.

8.

Human Monoclonal Antibody 81.39a Effectively Neutralizes Emerging Influenza A Viruses of Group 1 and 2 Hemagglutinins.

Marjuki H, Mishin VP, Chai N, Tan MW, Newton EM, Tegeris J, Erlandson K, Willis M, Jones J, Davis T, Stevens J, Gubareva LV.

J Virol. 2016 Nov 14;90(23):10446-10458. doi: 10.1128/JVI.01284-16. Print 2016 Dec 1.

9.

Enhanced Genetic Characterization of Influenza A(H3N2) Viruses and Vaccine Effectiveness by Genetic Group, 2014-2015.

Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM.

J Infect Dis. 2016 Oct 1;214(7):1010-9. doi: 10.1093/infdis/jiw181. Epub 2016 May 6. Erratum in: J Infect Dis. 2017 Jun 1;215(11):1774.

10.

Molecular Characterizations of Surface Proteins Hemagglutinin and Neuraminidase from Recent H5Nx Avian Influenza Viruses.

Yang H, Carney PJ, Mishin VP, Guo Z, Chang JC, Wentworth DE, Gubareva LV, Stevens J.

J Virol. 2016 May 27;90(12):5770-5784. doi: 10.1128/JVI.00180-16. Print 2016 Jun 15.

11.

Standardizing the influenza neuraminidase inhibition assay among United States public health laboratories conducting virological surveillance.

Okomo-Adhiambo M, Mishin VP, Sleeman K, Saguar E, Guevara H, Reisdorf E, Griesser RH, Spackman KJ, Mendenhall M, Carlos MP, Healey B, St George K, Laplante J, Aden T, Chester S, Xu X, Gubareva LV.

Antiviral Res. 2016 Apr;128:28-35. doi: 10.1016/j.antiviral.2016.01.009. Epub 2016 Jan 22.

PMID:
26808479
12.

Effectiveness of seasonal influenza vaccine in preventing influenza primary care visits and hospitalisation in Auckland, New Zealand in 2015: interim estimates.

Bissielo A, Pierse N, Huang QS, Thompson MG, Kelly H, Mishin VP, Turner N; SHIVERS.

Euro Surveill. 2016;21(1). doi: 10.2807/1560-7917.ES.2016.21.1.30101.

13.

Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir.

Tamura D, DeBiasi RL, Okomo-Adhiambo M, Mishin VP, Campbell AP, Loechelt B, Wiedermann BL, Fry AM, Gubareva LV.

J Infect Dis. 2015 Oct 15;212(8):1209-13. doi: 10.1093/infdis/jiv245. Epub 2015 May 5.

PMID:
25943200
14.

Neuraminidase Mutations Conferring Resistance to Oseltamivir in Influenza A(H7N9) Viruses.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Davis CT, Villanueva JM, Fry AM, Gubareva LV.

J Virol. 2015 May;89(10):5419-26. doi: 10.1128/JVI.03513-14. Epub 2015 Mar 4.

15.

Application of a seven-target pyrosequencing assay to improve the detection of neuraminidase inhibitor-resistant Influenza A(H3N2) viruses.

Tamura D, Okomo-Adhiambo M, Mishin VP, Guo Z, Xu X, Villanueva J, Fry AM, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2015 Apr;59(4):2374-9. doi: 10.1128/AAC.04939-14. Epub 2015 Feb 2.

16.

Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Marjuki H, Mishin VP, Chesnokov AP, Jones J, De La Cruz JA, Sleeman K, Tamura D, Nguyen HT, Wu HS, Chang FY, Liu MT, Fry AM, Cox NJ, Villanueva JM, Davis CT, Gubareva LV.

J Infect Dis. 2015 Jan 15;211(2):249-57. doi: 10.1093/infdis/jiu447. Epub 2014 Aug 14.

PMID:
25124927
17.

An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza A virus subtype H7N9 and protects mice from lethality.

Marjuki H, Mishin VP, Chesnokov AP, De La Cruz JA, Fry AM, Villanueva J, Gubareva LV.

J Infect Dis. 2014 Aug 1;210(3):435-40. doi: 10.1093/infdis/jiu105. Epub 2014 Feb 25.

18.

Antiviral susceptibility of variant influenza A(H3N2)v viruses isolated in the United States from 2011 to 2013.

Sleeman K, Mishin VP, Guo Z, Garten RJ, Balish A, Fry AM, Villanueva J, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2014;58(4):2045-51. doi: 10.1128/AAC.02556-13. Epub 2014 Jan 21.

19.

Antiviral susceptibility of highly pathogenic avian influenza A(H5N1) viruses isolated from poultry, Vietnam, 2009-2011.

Nguyen HT, Nguyen T, Mishin VP, Sleeman K, Balish A, Jones J, Creanga A, Marjuki H, Uyeki TM, Nguyen DH, Nguyen DT, Do HT, Klimov AI, Davis CT, Gubareva LV.

Emerg Infect Dis. 2013 Dec;19(12):1963-71. doi: 10.3201/eid1912.130705.

20.

The effect of the MDCK cell selected neuraminidase D151G mutation on the drug susceptibility assessment of influenza A(H3N2) viruses.

Mishin VP, Sleeman K, Levine M, Carney PJ, Stevens J, Gubareva LV.

Antiviral Res. 2014 Jan;101:93-6. doi: 10.1016/j.antiviral.2013.11.001. Epub 2013 Nov 14.

PMID:
24239666
21.

Cell culture-selected substitutions in influenza A(H3N2) neuraminidase affect drug susceptibility assessment.

Tamura D, Nguyen HT, Sleeman K, Levine M, Mishin VP, Yang H, Guo Z, Okomo-Adhiambo M, Xu X, Stevens J, Gubareva LV.

Antimicrob Agents Chemother. 2013 Dec;57(12):6141-6. doi: 10.1128/AAC.01364-13. Epub 2013 Sep 30.

22.

Bioluminescence-based neuraminidase inhibition assay for monitoring influenza virus drug susceptibility in clinical specimens.

Marjuki H, Mishin VP, Sleeman K, Okomo-Adhiambo M, Sheu TG, Guo L, Xu X, Gubareva LV.

Antimicrob Agents Chemother. 2013 Nov;57(11):5209-15. doi: 10.1128/AAC.01086-13. Epub 2013 Aug 5.

23.

Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.

Nguyen HT, Trujillo AA, Sheu TG, Levine M, Mishin VP, Shaw M, Ades EW, Klimov AI, Fry AM, Gubareva LV.

Antiviral Res. 2012 Mar;93(3):381-6. doi: 10.1016/j.antiviral.2012.01.006. Epub 2012 Feb 7.

PMID:
22330888
24.

Neuraminidase inhibitor susceptibility testing in human influenza viruses: a laboratory surveillance perspective.

Okomo-Adhiambo M, Sleeman K, Ballenger K, Nguyen HT, Mishin VP, Sheu TG, Smagala J, Li Y, Klimov AI, Gubareva LV.

Viruses. 2010 Oct;2(10):2269-89. doi: 10.3390/v2102269. Epub 2010 Oct 13. Erratum in: Viruses. 2011 Aug;3(8):1415-6.

25.

Receptor-binding specificity of the human parainfluenza virus type 1 hemagglutinin-neuraminidase glycoprotein.

Alymova IV, Portner A, Mishin VP, McCullers JA, Freiden P, Taylor GL.

Glycobiology. 2012 Feb;22(2):174-80. doi: 10.1093/glycob/cwr112. Epub 2011 Aug 16.

26.

Detection of hemagglutinin variants of the pandemic influenza A (H1N1) 2009 virus by pyrosequencing.

Levine M, Sheu TG, Gubareva LV, Mishin VP.

J Clin Microbiol. 2011 Apr;49(4):1307-12. doi: 10.1128/JCM.02424-10. Epub 2011 Feb 9.

27.

H1N1pdm influenza infection in hospitalized cancer patients: clinical evolution and viral analysis.

Souza TM, Salluh JI, Bozza FA, Mesquita M, Soares M, Motta FC, Pitrowsky MT, de Lourdes Oliveira M, Mishin VP, Gubareva LV, Whitney A, Rocco SA, Gonçalves VM, Marques VP, Velasco E, Siqueira MM.

PLoS One. 2010 Nov 30;5(11):e14158. doi: 10.1371/journal.pone.0014158.

28.

Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.

Gubareva LV, Trujillo AA, Okomo-Adhiambo M, Mishin VP, Deyde VM, Sleeman K, Nguyen HT, Sheu TG, Garten RJ, Shaw MW, Fry AM, Klimov AI.

Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.

PMID:
21149922
29.

Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.

Nguyen HT, Sheu TG, Mishin VP, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Sep;54(9):3671-7. doi: 10.1128/AAC.00581-10. Epub 2010 Jun 28.

30.

In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses.

Sleeman K, Mishin VP, Deyde VM, Furuta Y, Klimov AI, Gubareva LV.

Antimicrob Agents Chemother. 2010 Jun;54(6):2517-24. doi: 10.1128/AAC.01739-09. Epub 2010 Mar 29.

31.

N-linked glycan at residue 523 of human parainfluenza virus type 3 hemagglutinin-neuraminidase masks a second receptor-binding site.

Mishin VP, Watanabe M, Taylor G, Devincenzo J, Bose M, Portner A, Alymova IV.

J Virol. 2010 Mar;84(6):3094-100. doi: 10.1128/JVI.02331-09. Epub 2010 Jan 6.

32.

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

Triana-Baltzer GB, Gubareva LV, Nicholls JM, Pearce MB, Mishin VP, Belser JA, Chen LM, Chan RW, Chan MC, Hedlund M, Larson JL, Moss RB, Katz JM, Tumpey TM, Fang F.

PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.

33.

Effect of hemagglutinin-neuraminidase inhibitors BCX 2798 and BCX 2855 on growth and pathogenicity of Sendai/human parainfluenza type 3 chimera virus in mice.

Watanabe M, Mishin VP, Brown SA, Russell CJ, Boyd K, Babu YS, Taylor G, Xiong X, Yan X, Portner A, Alymova IV.

Antimicrob Agents Chemother. 2009 Sep;53(9):3942-51. doi: 10.1128/AAC.00220-09. Epub 2009 Jun 29.

34.

Treatment of influenza A (H1N1) virus infections in mice and ferrets with cyanovirin-N.

Smee DF, Bailey KW, Wong MH, O'Keefe BR, Gustafson KR, Mishin VP, Gubareva LV.

Antiviral Res. 2008 Dec;80(3):266-71. doi: 10.1016/j.antiviral.2008.06.003. Epub 2008 Jul 2.

35.

Loss of the N-linked glycan at residue 173 of human parainfluenza virus type 1 hemagglutinin-neuraminidase exposes a second receptor-binding site.

Alymova IV, Taylor G, Mishin VP, Watanabe M, Murti KG, Boyd K, Chand P, Babu YS, Portner A.

J Virol. 2008 Sep;82(17):8400-10. doi: 10.1128/JVI.00474-08. Epub 2008 Jun 25.

36.

Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor.

Smee DF, Wandersee MK, Checketts MB, O'Keefe BR, Saucedo C, Boyd MR, Mishin VP, Gubareva LV.

Antivir Chem Chemother. 2007;18(6):317-27.

PMID:
18320936
37.

Evaluation of methyl inosine monophosphate (MIMP) and peramivir activities in a murine model of lethal influenza A virus infection.

Mishin VP, Hayden FG, Signorelli KL, Gubareva LV.

Antiviral Res. 2006 Aug;71(1):64-8. Epub 2006 Mar 9.

PMID:
16581141
38.

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

Malakhov MP, Aschenbrenner LM, Smee DF, Wandersee MK, Sidwell RW, Gubareva LV, Mishin VP, Hayden FG, Kim DH, Ing A, Campbell ER, Yu M, Fang F.

Antimicrob Agents Chemother. 2006 Apr;50(4):1470-9.

39.

Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection.

Ison MG, Mishin VP, Braciale TJ, Hayden FG, Gubareva LV.

J Infect Dis. 2006 Mar 15;193(6):765-72. Epub 2006 Feb 13.

PMID:
16479509
40.

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Mishin VP, Hayden FG, Gubareva LV.

Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20.

41.

Effect of hemagglutinin glycosylation on influenza virus susceptibility to neuraminidase inhibitors.

Mishin VP, Novikov D, Hayden FG, Gubareva LV.

J Virol. 2005 Oct;79(19):12416-24.

42.

Protection afforded by intranasal immunization with the neuraminidase-lacking mutant of influenza A virus in a ferret model.

Mishin VP, Nedyalkova MS, Hayden FG, Gubareva LV.

Vaccine. 2005 Apr 22;23(22):2922-7.

PMID:
15780741
43.

[Localization of tick-borne encephalitis virus protein E antigenic determinant recognized by antihemagglutinating monoclonal antibodies using a phage-display peptide library].

Loktev AV, Kuvshinov VN, Melamed NV, Ivanisenko VA, Mishin VP, Il'ichev AA.

Vopr Virusol. 2002 Mar-Apr;47(2):31-4. Russian.

PMID:
12046465
44.

A 'minimal' approach in design of flavivirus infectious DNA.

Mishin VP, Cominelli F, Yamshchikov VF.

Virus Res. 2001 Dec 4;81(1-2):113-23.

PMID:
11682130
45.

[Structure of over lapping region of ICP18.5 and gB genes of type 1 bovine herpesvirus strain TK-A].

Tikunova NV, Oreshkova SF, Mishin VP, Kononova GL, Il'ichev AA.

Vopr Virusol. 2001 May-Jun;46(3):42-6. Russian.

PMID:
11450144
46.

[Markers of hepatitis C and its various genotypes in patients from Novosibirsk].

Shustov AV, Mishin VP, Maksiutov AZ, Kiseleva NN, Sakharova EG, Tolokonskaia NP, Robertson BJ, Netesov SV.

Vopr Virusol. 2000 Nov-Dec;45(6):22-7. Russian.

PMID:
11200641
47.

Genetic diversity of hantaviruses associated with hemorrhagic fever with renal syndrome in the far east of Russia.

Yashina LN, Patrushev NA, Ivanov LI, Slonova RA, Mishin VP, Kompanez GG, Zdanovskaya NI, Kuzina II, Safronov PF, Chizhikov VE, Schmaljohn C, Netesov SV.

Virus Res. 2000 Sep;70(1-2):31-44.

PMID:
11074123
48.

[Construction of reference panel of immune serum against hepatitis C virus with standard level of IgG antibodies].

Kanev AN, Shalunova NV, Netesov SV, Iastrebova ON, Musina EE, Bocharova NG, Mishin VP, Kiselev NN, Shystov AV, Smerdova MA, Bektimirov TA.

Vopr Virusol. 2000 Jul-Aug;45(4):42-7. Russian.

PMID:
10971966
49.

[Gene Nc73EF of Drosophila melanogaster encodes a protein highly homologous to E1 subunit of human 2-oxoglutarate dehydrogenase].

Gruntenko NE, Kochetov AV, Makarova KS, Mishin VP, Lukasheva VV, Ptitsyn AA, Kokoza VA.

Genetika. 1998 Jan;34(1):32-7. Russian.

PMID:
9532450
50.

[Use of a phage peptide library in mapping the group-specific hemagglutinating domain of alpha-virus glycoprotein E2].

Kuz'micheva GA, Kuvshinov VN, Razumov IA, Ivanisenko VA, Eroshkin AM, Mishin VP, Ushakova TA, Loktev VB, Il'ichev AA.

Mol Gen Mikrobiol Virusol. 1997;(4):25-9. Russian.

PMID:
9411217

Supplemental Content

Loading ...
Support Center